Improvements with Alemtuzumab in clinical and MRI disease activity outcomes in RRMS patients across age groups: CARE-MS I and II 8-year follow-upS. Eichau,R. Arroyo,A. D. Bass,A. Boster, A. N. Boyko,D. Graves, C. Ionete,V. Limmroth,C. Navas,D. Pelletier,C. Pozzilli, J. Ravenscroft,L. Sousa, M. Tintore,B. M. Uitdehaag,D. P. Baker,N. Daizadeh,Z. Choudhry,D. RogEUROPEAN JOURNAL OF NEUROLOGY（2019）引用 0|浏览5暂无评分AI 理解论文溯源树样例生成溯源树，研究论文发展脉络Chat Paper正在生成论文摘要
